Weight Wise Weight Loss Centers Now Offers Telehealth Across Maryland & Florida. Call Today!
Those struggling with obesity and overweight may benefit from a new drug called tirzepatide, marketed under the brand name Mounjaro. Type 2 diabetes can be treated with this injectable medicine.
However, some doctors are giving it “off-label” to help their patients lose weight even though they don’t have diabetes.
Mounjaro (tirzepatide) can be used in conjunction with a healthy diet and regular exercise to help diabetics significantly reduce their blood sugar levels and their overall body weight. Even in non-diabetic adults, it has been demonstrated to promote weight loss.
It’s important to be informed of the possible hazards and side effects, like with any drug. What do you need to know about Mounjaro (tirzepatide) if you’re thinking about using it to help you lose weight? After reading this post, you can consider all your queries on the subject.
Like other well-known GLP-1 medications, such as Novo Nordisk’s Wegovy, Mounjaro is an injectable prescription taken once weekly to help control blood sugar levels. Although it is currently only approved for use in people with type 2 diabetes, it has shown potential as a weight loss medicine.
Clinical trials of Mounjaro (tirzepatide) indicated that it helped lower hemoglobin A1C levels and promote weight loss when taken at therapeutic doses. Mounjaro (tirzepatide) should be used with alterations to one’s diet, sleeping routine, and physical activity. Medicine is thought to have the greatest impact when combined with expert guidance and encouragement.
A starting dose of Mounjaro of 2.5 mg is suggested. After four weeks, doses may be raised in 2.5 mg increments, as tolerated, up to a maximum of 15 mg once weekly. Doses are set and monitored by a healthcare provider and may be changed to help individuals accomplish their blood sugar, weight loss, and metabolic health objectives.
The FDA has approved Mounjaro for use in individuals with type-2 diabetes mellitus but not for weight loss. This approval is effective as of May 2022.
However, research has shown that the product’s main ingredient is both safe and helpful for treating obesity. Moreover, Fast Track status for treating overweight and obesity was given to Mounjaro (tirzepatide) by the FDA in October 2022.
The Food and Drug Administration may approve use in weight reduction far sooner than previously thought.
As shown by research results, Mounjaro (tirzepatide) is an excellent tool for weight loss for individuals with insulin resistance or prediabetes, just as it is for adults with type-2 diabetes.
In a clinical study called SURMOUNT-1, over 2,500 patients in a research experiment who were overweight or obese lost considerable amounts of weight while taking Mounjaro (tirzepatide) once weekly.
Over the course of 72 weeks, those who took tirzepatide lost an average of 15–20 percent of their body weight (about 16 and a half months). On average, those who received the placebo (an injection that included no active ingredients) lost less weight (3%).
Mounjaro (tirzepatide) is groundbreaking because it combines two different types of drugs into a single formulation for the first time: a glucagon-like peptide-1 (GLP-1) receptor agonist and a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Because of this, Mounjaro (tirzepatide) is classified as a GLP-1/GIP receptor agonist.
Ozempic (Compounded Semaglutide) is simply a GLP-1 agonist and does not affect the GIP receptors. This means that Mounjaro actually acts to lower postprandial glucose concentration, where as Ozempic does not.
When it comes down to choosing the right option for you, it is necessary to consult a medical professional as everyone has a different body and different needs.
GLP-1 and GIP belong to a class of hormones known as incretins, secreted in response to food consumption. Mounjaro (tirzepatide) is effective because it mimics their actions. It involves instructing the pancreas to secrete insulin in response to a meal and sending a message to the liver to reduce glucose production. These actions aid in satiety, digestive slowdown, and glucose regulation.
In addition to its effect on glucose levels, Mounjaro (tirzepatide) also promotes weight loss through some other mechanisms:
Similar injectable weight loss drugs only imitate one incretin, GLP-1. Due to its dual incretin-like effects, Mounjaro (tirzepatide) may be more effective than existing weight-loss options.
Mounjaro (Tizerpatide) has the potential for adverse effects like any other medicine. These symptoms appear to be the most troublesome at the beginning of treatment or following a dosage increase. The majority of adverse effects are transient and easily treated.
Consult your doctor if any of these symptoms persist or are particularly bothersome. Moreover, drug interactions with Mounjaro (tirzepatide) have been reported. Please consult your doctor and pharmacist before changing your current prescription regimen.
Obesity is detrimental to health in virtually every way, affecting everything from the reproductive ability to memory and emotional stability. Obesity is linked to several serious health problems, including diabetes, heart disease, and cancer.
Reasons for this catastrophe vary, some as simple as mechanical stress from carrying extra weight and others involving intricate adjustments to hormone levels and metabolic processes.
Due to the health hazards associated with obesity and the difficulties many patients have in losing weight and keeping it off, there is a constant demand for additional treatment choices.
Based on the new study’s results, tirzepatide at its maximum dose may be as effective as bariatric surgery.
Suppose you are overweight and experiencing health problems because of your weight.
In that case, you may be a candidate for Mounjaro tirzepatide injections.
Injections of Mounjaro (tirzepatide) are not the best course of treatment for everyone, so it’s essential to discuss the possibility with your primary care physician.
Receive updates on promotions, discounts and new weight loss products!
Disclaimer:
Generic Compounded GLP medications we offer are obtained from compounded pharmacies.
The medication you may be prescribed is a generic compounded medication and is not associated with the Novo Nordisk™ company or the brand-name medications Saxenda®, Victoza®, Rybelsus ®, Wegovy® or Ozempic®. or any other medications that are registered with Novo Nordisk™.
We are also not affiliated with the Eli Lily™ Company or any of their brand medications like Mounjaro, Trulicity, or any other medications that are registered with Eli Lily™.
© Weight Wise Weight Loss Centers | Powered by 7ten Digital Marketing |